Healthcare and Societal Costs in Patients with COPD and Breathlessness after Completion of a Comprehensive Rehabilitation Program. (4th March 2021)

• Record Type: Journal Article
• Authors: Verberkt, Cornelia A.; van den Beuken-van Everdingen, Marieke H. J.; Dirksen, Carmen D.; Schols, Jos M. G. A.; Vanfleteren, Lowie E. G. W.; Franssen, Frits M. E.; Groenen, Miriam T. J.; Wouters, Emiel F. M.; Janssen, Daisy J. A.
• Is Part Of: COPD. Volume 18:Number 2(2021)
• Page Start: 170
• Page End: 180
• Publication Date: 2021-03-04
• Subjects: COPD -- breathlessness -- healthcare utilization -- societal costs; Lungs -- Diseases, Obstructive -- Periodicals; 616.24
• DOI: 10.1080/15412555.2020.1868420
• Languages: English
• ISSNs: 1541-2555

Abstract

Abstract: Breathlessness is one of the most frequent symptoms in chronic obstructive pulmonary disease (COPD). COPD may result in disability, decreased productivity and increased healthcare costs. The presence of comorbidities increases healthcare utilization. However, the impact of breathlessness burden on healthcare utilization and daily activities is unclear. This study's goal was to analyze the impact of breathlessness burden on healthcare and societal costs. In this observational single-center study, patients with COPD were followed-up for 24 months after completion of a comprehensive pulmonary rehabilitation program. Every three months participants completed a cost questionnaire, covering healthcare utilization and impact on daily activities. The results were compared between participants with low (modified Medical Research Council (mMRC) grade <2; LBB) and high baseline breathlessness burden (mMRC grade ≥2; HBB). Healthcare costs in year 1 were €7302 (95% confidence interval €6476–€8258) for participants with LBB and €10, 738 (€9141–€12, 708) for participants with HBB. In year 2, costs were €8830 (€7372-€10, 562) and €14, 933 (€12, 041–€18, 520), respectively. Main cost drivers were hospitalizations, contact with other healthcare professionals and rehabilitation. Costs outside the healthcare sector in year 1 were €682 (€520–€900) for participants with LBB and €1520 (€1210–€1947) for participants with HBB. In year 2, costs were €829 (€662–€1046) and €1457 (€1126–€1821) respectively. HBB in patients with COPD is associated with higher healthcare and societal costs, which increases over time. This study highlights the relevance of reducing costs with adequate breathlessness relief. When conventional approaches fail to improve breathlessness, a personalized holistic approach is warranted.